ACADIA Pharmaceuticals
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 7 disclosed transactions, ACADIA Pharmaceuticals concentrates its licensing activity in Neurology, RareDisease. ACADIA Pharmaceuticals pays a 1.50x premium over market median. Their most common deal structure is License, with an average disclosed value of $779M. Most recent activity: 2024.
Pipeline coverage & gaps
ACADIA Pharmaceuticals has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 5 | $86M | $710M |
| Collaboration | 1 | $60M | $967M |
| Acquisition | 1 | $53M | $940M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2024 | SAN711 | Saniona | essential tremor | preclinical | $28M | $610M |
| 2023 | trofinetide | Neuren Pharmaceuticals Limited | Rett syndrome | approved | $100M | $527M |
| 2023 | trofinetide and NNZ-2591 | Neuren Pharmaceuticals | rett syndrome | approved | $100M | $954M |
| 2023 | Trofinetide (ex-North America) and NNZ-2591 (worldwide) | Neuren Pharmaceuticals | Rett syndrome and Fragile X syndrome | approved | $100M | $527M |
| 2023 | NNZ-2591 and trofinetide | Neuren Pharmaceuticals | Fragile X syndrome | approved | $100M | $931M |
| 2022 | SYNGAP1, MECP2 (Rett syndrome), and undisclosed neurodevelopmental target | Stoke Therapeutics | SYNGAP1 syndrome, Rett syndrome, undisclosed neurodevelopmental disorder | preclinical | $60M | $967M |
| 2020 | CerSci pain program | CerSci Therapeutics | chronic pain | preclinical | $53M | $940M |
How this is computed
For each ACADIA Pharmaceuticals deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 2.703, clamped to [0.7, 1.5].